SLS — SELLAS LIFE SCIENCES GROUP INC (Healthcare >> Biotechnology)
SLS FAQ
What is SLS's ROE?
SELLAS LIFE SCIENCES GROUP INC reports a Return on Equity (ROE) of -27.42%.
What is SLS's dividend yield?
SELLAS LIFE SCIENCES GROUP INC offers a dividend yield of 0.00%.
What is SLS's Deepscope Quality Score?
Deepscope rates SLS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SLS?
Deepscope's AI Timing Score for SLS is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SLS belong to?
SELLAS LIFE SCIENCES GROUP INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.04
Price
0.85
(10.38%)
Day Change
|
|
|---|
SLS Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.15 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.04 |
| PBV / Sector |
15.25 / 4.58
|
| Earning Per Share | -0.16 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
89.38 M
|
| Average 1W Daily Value |
105.28 M
GREAT
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
47% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-05 09:11:52 |
| Symbol | SLS |
| Name | SELLAS LIFE SCIENCES GROUP INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 196.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,637.95 / 8,655.90 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7 Times Square, New York, NY, United States, 10036
Phone: 646 200 5278
Website: https://sellaslifesciences.com
Sector: Healthcare >> Biotechnology
Description: SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google